Splenic artery: Peak systolic velocity of normal fetuses

Objective To establish a reference range of splenic artery peak systolic velocity 1(SpA-PSV) in the normal singleton pregnancies (14-40 weeks). Methods A prospective descriptive study was conducted on uncomplicated singleton pregnancies with normal fetuses and accurate gestational age were recruited...

Full description

Saved in:
Bibliographic Details
Main Authors: Tongsong T., Tongprasert F., Srisupundit K., Luewan S.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-77950628241&partnerID=40&md5=a64aa9e949c83172c51683af2607641c
http://www.ncbi.nlm.nih.gov/pubmed/19562358
http://cmuir.cmu.ac.th/handle/6653943832/2589
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
Description
Summary:Objective To establish a reference range of splenic artery peak systolic velocity 1(SpA-PSV) in the normal singleton pregnancies (14-40 weeks). Methods A prospective descriptive study was conducted on uncomplicated singleton pregnancies with normal fetuses and accurate gestational age were recruited into the study. The Doppler measurements of SpA-PSV were performed by the experienced sonographers with the high-resolution machine (Aloka Prosound alpha-10, Tokyo, Japan, or Voluson E8, GE Healthcare, USA). Results A total of 540 measurements were performed, ranging from 15 to 30 for each gestational week (GA). The best regression model between GA and SpA-PSV was observed to be linear function with an equation as follows: SpA-PSV (cm/s) = -1.433 +1.186 (GA, weeks) (r2 = 0.573). The table of nomogram for various percentile ranges was constructed. The results show a continuous increase in SpA-PSV over the period from 14 to 40 weeks. Conclusion A nomogram for SpA-PSV for each GA during 14-40 weeks was constructed. This reference range may be a useful non-invasive tool in risk assessment for fetal anemia, especially due to homozygous alpha-thalasse-mia-1 or fetal isoimmunization.